223 related articles for article (PubMed ID: 15146102)
1. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women.
Cheng WC; Yen ML; Hsu SH; Chen KH; Tsai KS
Endocrine; 2004; 23(2-3):215-8. PubMed ID: 15146102
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women.
Lasco A; Cannavò S; Gaudio A; Morabito N; Basile G; Nicita-Mauro V; Frisina N
Eur J Endocrinol; 2002 Oct; 147(4):461-5. PubMed ID: 12370106
[TBL] [Abstract][Full Text] [Related]
3. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.
Tsai KS; Yen ML; Pan HA; Wu MH; Cheng WC; Hsu SH; Yen BL; Huang KE
Osteoporos Int; 2001 Dec; 12(12):1020-5. PubMed ID: 11846327
[TBL] [Abstract][Full Text] [Related]
5. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms for altered reproductive function in female rats following neonatal administration of raloxifene.
Tena-Sempere M; Barreiro ML; Aguilar E; Pinilla L
Eur J Endocrinol; 2004 Mar; 150(3):397-403. PubMed ID: 15012627
[TBL] [Abstract][Full Text] [Related]
7. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
[TBL] [Abstract][Full Text] [Related]
8. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
Anderson PW; Cox DA; Sashegyi A; Paul S; Silfen SL; Walsh BW
Maturitas; 2001 Jul; 39(1):71-7. PubMed ID: 11451623
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene and pituitary secretion in post-menopausal women.
Lasco A; Cannavò S; Gaudio A; Morabito N; Trifiletti A; Di Cesare E; Basile G; Nicita-Mauro V; Frisina N
J Endocrinol Invest; 2002; 25(10 Suppl):95-6. PubMed ID: 12508935
[No Abstract] [Full Text] [Related]
10. Evidence for an estrogen-like action of raloxifene upon the hypothalamic-pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats.
Pinilla L; Gonzalez LC; Tena-Sempere M; Aguilar E
Neurosci Lett; 2001 Oct; 311(3):149-52. PubMed ID: 11578816
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
Usall J; Huerta-Ramos E; Labad J; Cobo J; Núñez C; Creus M; Parés GG; Cuadras D; Franco J; Miquel E; Reyes JC; Roca M;
Schizophr Bull; 2016 Mar; 42(2):309-17. PubMed ID: 26591005
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
Vogelvang TE; Leurs JR; van der Mooren MJ; Mijatovic V; Hendriks DF; Neele SJ; Netelenbos JC; Kenemans P
Menopause; 2004; 11(1):110-5. PubMed ID: 14716191
[TBL] [Abstract][Full Text] [Related]
13. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
[TBL] [Abstract][Full Text] [Related]
14. Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk.
Cerquetani E; Vitale C; Mercuro G; Fini M; Zoncu S; Rosano GM
Gynecol Endocrinol; 2004 Jun; 18(6):291-8. PubMed ID: 15497491
[TBL] [Abstract][Full Text] [Related]
15. Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women.
Dias AR; de Mello NR; Eluf Gebara OC; Nussbacher A; Wajngarten M; Petti DA
Climacteric; 2008 Oct; 11(5):390-6. PubMed ID: 18781483
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women.
Giltay EJ; Duschek EJ; Katan MB; Zock PL; Neele SJ; Netelenbos JC
J Endocrinol; 2004 Sep; 182(3):399-408. PubMed ID: 15350182
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of oestrogen-induced prolactin release by medroxyprogesterone acetate.
Castelo-Branco C; Palacios S; Martinez de Osaba MJ; Balasch J; Fortuny A; Vanrell J
Maturitas; 1994 Dec; 20(2-3):145-50. PubMed ID: 7715466
[TBL] [Abstract][Full Text] [Related]
18. Oestrogenic effects of neonatal administration of raloxifene on hypothalamic-pituitary-gonadal axis in male and female rats.
Pinilla L; González LC; Gaytán F; Tena-Sempere M; Aguilar E
Reproduction; 2001 Jun; 121(6):915-24. PubMed ID: 11373178
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of unopposed versus opposed hormone therapy, tibolone, and raloxifene on substance p levels.
Kukuvitis A; Kourtis A; Papaiconomou N; Zournatzi V; Makedos G; Panidis D
Fertil Steril; 2003 Jul; 80(1):96-8. PubMed ID: 12849808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
